How Wegovy Is Marketed in the UK — and What the Rules Actually Say

Why can't Wegovy be advertised on TV or social media the way other products are?

The short answer is that UK law draws a hard line between medicines and consumer goods. Prescription-only medicines cannot be promoted to the public, full stop. That prohibition comes from Part 14 of the Human Medicines Regulations 2012, which the MHRA enforces. It covers TV, print, social media and paid-search ads alike. Novo Nordisk, the maker of Wegovy, can run campaigns aimed at healthcare professionals and can publish prescribing information in professional channels, but a billboard telling the public to ask their doctor about Wegovy would be a breach.

The MHRA has also been specific about GLP-1 medicines: its published guidance makes clear that semaglutide and tirzepatide are not assessed or licensed for rapid or cosmetic weight loss. That framing matters, because some of the most visible content about these medicines online (particularly on social media) comes from accounts that are not registered pharmacies and not subject to the same constraints. The MHRA's Yellow Card reporting scheme allows the public to flag suspect promotional material as well as side effects.

What registered pharmacies and clinical services can do is describe the medicine factually: what it's licensed for, how clinical trials performed, what the eligibility criteria are, how to access it through a regulated route. That's information, not a sales pitch. The distinction matters for anyone trying to make sense of what they read.

Does the volume of content about Wegovy online mean it's being illegally marketed?

Not necessarily, and this is probably the most common misconception worth setting down gently. Most of the high-volume content about semaglutide comes from news outlets, NHS pages, NICE appraisals, academic commentary and patient-information resources, none of which constitute advertising. Journalism about a medicine's approval, a NICE guidance document, an NHS explainer: all of that is legitimate public discourse.

Where the line gets crossed is when content is clearly designed to make you want to buy a specific product, urgency cues, discounts, celebrity endorsements tied to purchase links, before-and-after imagery presented as a sales device. These are the patterns regulators and the Advertising Standards Authority (ASA) watch for. The NHS medicines page on semaglutide is a useful benchmark: it's factual, balanced and doesn't push you toward a purchase. Regulated clinical services follow the same principle.

The grey area most readers encounter is influencer content. Someone describing their personal experience with Wegovy isn't automatically illegal, but when that content is paid for by a pharmacy or includes a referral link, it enters regulated territory fast. The ASA has become more active in this space as GLP-1 use has grown. If you're reading a glowing account and can't find a disclosure, treat it accordingly.

How does Wegovy's UK market position affect what you see?

Wegovy launched in the UK in 2023 with considerable pent-up demand, partly driven by Ozempic's visibility abroad and a significant body of trial evidence, and the story of when Wegovy hit the market helps explain why public interest built so quickly. The semaglutide market in the UK has grown quickly, and understanding how Wegovy sits within it helps contextualise the volume of information in circulation. Novo Nordisk's approach in the UK has been to focus on healthcare professional education and patient-support programmes rather than consumer campaigns (in keeping with POM restrictions) while third-party media and clinical commentary have done most of the public-awareness work.

The MHRA and NICE have also contributed substantially to public knowledge through their appraisals and safety updates. NICE's technology appraisal TA875 recommended semaglutide within specific NHS pathways, which generated mainstream news coverage. That coverage is not marketing by Novo Nordisk; it's the normal public reporting that follows a major regulatory decision.

For people looking at the private market, the picture is more varied. Prices, service models and clinical rigour differ between providers, and some of what gets presented as information is closer to sales material. The Wegovy price comparison context for the UK is worth reading alongside any service you're considering. It's also worth checking whether the pharmacy you're looking at appears on the GPhC register at pharmacyregulation.org/registers, a few seconds that saves a great deal of uncertainty.

What should you look for when evaluating content about Wegovy?

A few markers separate educational content from promotional material. Is the publisher a registered pharmacy or clinical service? Are citations to NHS, NICE or published trial data included? Does the page acknowledge that a prescriber decides suitability, rather than inviting you straight to a basket? Does it describe side effects and contraindications honestly, or only the benefits? Thorough services will also cover less-discussed physical changes, such as whether Wegovy can contribute to stretch marks, rather than presenting only positive outcomes.

Content that talks only about results, quotes unusually large weight-loss figures without a trial reference, uses language like 'guaranteed' or promises speed without clinical caveats, these are signs the content is doing something other than informing you. The same applies to social media accounts offering semaglutide without mention of a prescriber or clinical assessment. The grey market for semaglutide is a real safety concern, and it is often found precisely in channels that operate outside the marketing rules that registered services must follow.

At nume, every piece of content is written to be accurate and to defer clinical decisions to our prescribers. There are no discount codes, no urgency prompts, no before-and-after framing. If you're trying to work out whether a GLP-1 treatment could be right for you, the weight-loss treatment overview is a good starting point, and our prescribers are available through a free consultation whenever you're ready to have that conversation properly.